These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 34560863)
1. Optimizing inhalation therapy in the aspect of peak inhalation flow rate in patients with chronic obstructive pulmonary disease or asthma. Hua JL; Ye XF; Du CL; Xie N; Zhang JQ; Li M; Zhang J BMC Pulm Med; 2021 Sep; 21(1):302. PubMed ID: 34560863 [TBL] [Abstract][Full Text] [Related]
2. Effect of PIFR-based optimised inhalation therapy in patients recovering from acute exacerbation of chronic obstructive pulmonary disease: protocol of a prospective, multicentre, superiority, randomised controlled trial. Hua J; Zhang W; Cao HF; Du CL; Ma JY; Zuo YH; Zhang J BMJ Open; 2020 May; 10(5):e034804. PubMed ID: 32385061 [TBL] [Abstract][Full Text] [Related]
3. Prevalence and predictors of suboptimal peak inspiratory flow rate in COPD patients. Harb HS; Laz NI; Rabea H; Abdelrahim MEA Eur J Pharm Sci; 2020 Apr; 147():105298. PubMed ID: 32151707 [TBL] [Abstract][Full Text] [Related]
4. Prevalence and factors associated with suboptimal peak inspiratory flow rates in COPD. Ghosh S; Pleasants RA; Ohar JA; Donohue JF; Drummond MB Int J Chron Obstruct Pulmon Dis; 2019; 14():585-595. PubMed ID: 30880948 [TBL] [Abstract][Full Text] [Related]
5. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler. Prime D; de Backer W; Hamilton M; Cahn A; Preece A; Kelleher D; Baines A; Moore A; Brealey N; Moynihan J J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):486-97. PubMed ID: 26372467 [TBL] [Abstract][Full Text] [Related]
6. Suboptimal peak inspiratory flow rate: a noticeable risk factor for inhaler concordance in patients with chronic airway diseases. Meng W; Xiong R; Zhao Z; Zeng H; Chen Y BMJ Open Respir Res; 2024 Apr; 11(1):. PubMed ID: 38642917 [TBL] [Abstract][Full Text] [Related]
7. Peak Inspiratory Flow Rate in Chronic Obstructive Pulmonary Disease: Implications for Dry Powder Inhalers. Ghosh S; Ohar JA; Drummond MB J Aerosol Med Pulm Drug Deliv; 2017 Dec; 30(6):381-387. PubMed ID: 28933581 [TBL] [Abstract][Full Text] [Related]
8. Can patients achieve sufficient peak inspiratory flow rate (PIFR) with Turbuhaler® during acute exacerbation of asthma? Mohd Rhazi NA; Muneswarao J; Abdul Aziz F; Ibrahim B; Kamalludin A; Soelar SA J Asthma; 2023 Aug; 60(8):1608-1612. PubMed ID: 36650693 [TBL] [Abstract][Full Text] [Related]
9. [Chinese expert consensus on standardized inhaler device application in stable chronic airway diseases (2023)]. Inhalation Therapy and Respiratory Rehabilitation Group, Respiratory Equipment Committee of China Association of Medical Equipment Zhonghua Jie He He Hu Xi Za Zhi; 2023 Nov; 46(11):1055-1067. PubMed ID: 37914418 [TBL] [Abstract][Full Text] [Related]
10. Suboptimal peak inspiratory flow rate in dry-powder inhaler users for chronic obstructive pulmonary disease in Korea. Moon JY; Kim SH; Kim Y; Lee H; Rhee CK; Ra SW; Lee CY; Park JH; Park YB; Yoo KH Pulm Pharmacol Ther; 2024 Jun; 85():102298. PubMed ID: 38604404 [TBL] [Abstract][Full Text] [Related]
11. Determinants of Suboptimal Peak Inspiratory Flow Rates among Patients with Chronic Obstructive Pulmonary Disease in Southwest, Nigeria. Arawomo AO; Erhabor GE; Tanimowo MO; Awopeju OF; Adewole OO; Adeniyi BO; Afolabi BA; Ekundayo MW West Afr J Med; 2023 May; 40(5):553-561. PubMed ID: 37247343 [TBL] [Abstract][Full Text] [Related]
12. Peak Inspiratory Flow Measured at Different Inhaler Resistances in Patients with Asthma. Haughney J; Lee AJ; McKnight E; Pertsovskaya I; O'Driscoll M; Usmani OS J Allergy Clin Immunol Pract; 2021 Feb; 9(2):890-896. PubMed ID: 33011302 [TBL] [Abstract][Full Text] [Related]
14. Peak inspiratory flow rate measurement by using In-Check DIAL for the different inhaler devices in elderly with obstructive airway diseases. Kawamatawong T; Khiawwan S; Pornsuriyasak P J Asthma Allergy; 2017; 10():17-21. PubMed ID: 28260934 [TBL] [Abstract][Full Text] [Related]
15. Wixela Inhub: Dosing Performance Cooper A; Parker J; Berry M; Wallace R; Ward J; Allan R J Aerosol Med Pulm Drug Deliv; 2020 Dec; 33(6):323-341. PubMed ID: 32429788 [No Abstract] [Full Text] [Related]
16. Inappropriate Peak Inspiratory Flow Rate in the Patients with Stable Chronic Obstructive Pulmonary Disease in Korea. Youn SH; Kim HJ; Park JS; Park SH; Kwon YS; Kim MA Tuberc Respir Dis (Seoul); 2024 Oct; 87(4):458-464. PubMed ID: 38659389 [TBL] [Abstract][Full Text] [Related]
17. Patterns of use of dry powder inhalers versus pressurized metered-dose inhalers devices in adult patients with chronic obstructive pulmonary disease or asthma: An observational comparative study. Ramadan WH; Sarkis AT Chron Respir Dis; 2017 Aug; 14(3):309-320. PubMed ID: 28774201 [TBL] [Abstract][Full Text] [Related]
18. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Brocklebank D; Ram F; Wright J; Barry P; Cates C; Davies L; Douglas G; Muers M; Smith D; White J Health Technol Assess; 2001; 5(26):1-149. PubMed ID: 11701099 [TBL] [Abstract][Full Text] [Related]
19. Prevalence and Factors Affecting the Optimal and Non-optimal Peak Inspiratory Flow Rate in Stable and Exacerbation Phases of Chronic Obstructive Pulmonary Disease and Bronchial Asthma in India. Murugaiya S; Murugesan B; S P Cureus; 2024 Apr; 16(4):e58670. PubMed ID: 38774171 [TBL] [Abstract][Full Text] [Related]
20. The economic burden of asthma and chronic obstructive pulmonary disease and the impact of poor inhalation technique with commonly prescribed dry powder inhalers in three European countries. Lewis A; Torvinen S; Dekhuijzen PN; Chrystyn H; Watson AT; Blackney M; Plich A BMC Health Serv Res; 2016 Jul; 16():251. PubMed ID: 27406133 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]